Compare · NVO vs ZVRA
NVO vs ZVRA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Zevra Therapeutics Inc. (ZVRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ZVRA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 295.2x ZVRA ($754.9M).
- Over the past year, NVO is down 22.5% and ZVRA is up 8.9% - ZVRA leads by 31.4 points.
- NVO has hit the wire 4 times in the past 4 weeks while ZVRA has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 9 for ZVRA).
- Company
- Novo Nordisk A/S
- Zevra Therapeutics Inc.
- Price
- $50.31-2.25%
- $12.76+0.12%
- Market cap
- $222.81B
- $754.9M
- 1M return
- +15.47%
- +0.83%
- 1Y return
- -22.53%
- +8.87%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest ZVRA
- Chief Legal & Compliance Thompson Rahsaan sold $438,304 worth of shares (34,557 units at $12.68) as part of a pre-agreed trading plan and converted options into 66,667 shares, increasing direct ownership by 67% to 80,235 units (SEC Form 4)
- Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
- SEC Form 4 filed by Director Favorito Tamara A
- SEC Form 4 filed by Director Secor Alicia
- SEC Form 4 filed by Director Watton Corey Michael
- SEC Form 4 filed by Director Calder Douglas W
- SEC Form 4 filed by Director Anderson Thomas
- SEC Form 4 filed by Director Shih Alvin
- Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
- Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA